Not exact matches
Though
uveal melanoma is rare — there are only 2,500 cases diagnosed in the United States each year — about half of patients will develop metastatic disease, and survival for patients with advanced disease has held steady
at nine months to a year for decades.
«This is the first study to show that a systemic therapy provides significant clinical benefit in a randomized fashion to advanced
uveal melanoma patients, who have very limited treatment options,» said Richard D. Carvajal, MD, a medical oncologist
at Memorial Sloan - Kettering and lead author on the study.
One hundred and one patients with metastatic
uveal melanoma
at 15 centers in the United States and Canada were randomized to receive either selumetinib or standard chemotherapy.
The appearance of the moles and the melanomas in these families can be unusual and affected families are also
at increased risk of other cancers such as mesothelioma and eye (
uveal) melanoma.